Yamamura T, et al. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS 2018, abstract 323.
Risicofactoren voor ‘late-onset’ epilepsie
aug 2018 | Diabetes, Epilepsie